NYSE:LLY

Eli Lilly and Stock Forecast, Price & News

$226.15

+2.06 (+0.92 %)

(As of 06/14/2021 04:00 PM ET)

Add

Compare

Today's Range

$221.39

▼

$226.62

50-Day Range

$180.55

▼

$233.54

52-Week Range

$129.21

▼

$235.85

Volume93,127 shs

Average Volume3.99 million shs

Market Capitalization$216.88 billion

P/E Ratio33.80

Dividend Yield1.52%

Beta0.24

30 days | 90 days | 365 days | Advanced Chart

Receive LLY News and Ratings via Email

Sign-up to receive the latest news and ratings for Eli Lilly and and its competitors with MarketBeat's FREE daily newsletter.

About Eli Lilly and

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Lilly to Participate in Guggenheim Biopharma Strategy Series
June 14, 2021 | finance.yahoo.com

Lilly Announces Webcast to Provide Diabetes Portfolio Update at ADA
June 11, 2021 | finance.yahoo.com

Eli Lilly's Internal Probe Clears Its COVID-19 Drug Plant; Memo Says Company Did Not Make False Statements: Reuters
June 11, 2021 | finance.yahoo.com

Pharma Stock Roundup: FDA Approval for NVO, PFE Products & Other Updates
June 11, 2021 | finance.yahoo.com

Eli Lilly internal inquiry finds firm did not lie to FDA
June 10, 2021 | msn.com

Mouth Cancer Treatment Market Overview, New Opportunities & SWOT Analysis by 2026 | Merck, Pfizer, Eli Lilly, Novartis
June 10, 2021 | marketwatch.com

EXCLUSIVE Eli Lilly memo says firm did not make false statements to FDA
June 10, 2021 | msn.com

ALX Oncology, Eli Lilly to Evaluate Gastric Cancer Treatment
June 10, 2021 | marketwatch.com

Osteoporosis Drugs Market 2021 Global Insights and Business Outlook – Eli Lilly, Novartis, Pfizer, Amgen, Merck, Novo nordisk
June 9, 2021 | marketwatch.com

Eli Lilly and (NYSE:LLY) Rating Reiterated by Truist Securities
June 8, 2021 | americanbankingnews.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NYSE
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNYSE:LLY
Previous Symbol
CUSIP53245710
CIK59478
Webwww.lilly.com
Phone317-276-2000
Employees35,000
Year Founded1876

Sales & Book Value

Annual Sales$24.54 billion
Price / Sales8.84
Cash Flow$9.03 per share
Price / Cash Flow25.04
Book Value$6.09 per share
Price / Book37.13

Profitability

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares959,025,000
Market Cap$216.88 billion
Next Earnings Date7/29/2021 (Estimated)
OptionableOptionable

Social Links

MarketRank^™

Overall MarketRank^™

1.97 out of 5 stars

Medical Sector

88th out of 2,099 stocks

Pharmaceutical Preparations Industry

38th out of 831 stocks

2.5 Analyst's Opinion

Consensus Rating
Eli Lilly and has received a consensus rating of Buy. The company's average rating score is 2.93, and is based on 11 buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $207.43, Eli Lilly and has a forecasted downside of 7.8% from its current price of $224.94.
Amount of Analyst Coverage
Eli Lilly and has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.8 Community Rank

Outperform Votes
Eli Lilly and has received 1,042 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Eli Lilly and has received 843 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Eli Lilly and has received 55.28% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Eli Lilly and and other stocks. Vote “Outperform” if you believe LLY will outperform the S&P 500 over the long term. Vote “Underperform” if you believe LLY will underperform the S&P 500 over the long term. You may vote once every thirty days.

1.7 Dividend Strength

Dividend Yield
Eli Lilly and has a dividend yield of 1.52%, which is in the bottom 25% of all stocks that pay dividends.
Dividend Growth
Eli Lilly and has only been increasing its dividend for 1 years.
Dividend Coverage
The dividend payout ratio of Eli Lilly and is 42.88%. This payout ratio is at a healthy, sustainable level, below 75%.
Dividend Sustainability
Based on earnings estimates, Eli Lilly and will have a dividend payout ratio of 40.14% next year. This indicates that Eli Lilly and will be able to sustain or increase its dividend.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Eli Lilly and insiders have sold 31,182.93% more of their company's stock than they have bought. Specifically, they have bought $249,759.00 in company stock and sold $78,131,944.00 in company stock.
Percentage Held by Insiders
Only 0.13% of the stock of Eli Lilly and is held by insiders.
Percentage Held by Institutions
81.63% of the stock of Eli Lilly and is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3 Earnings and Valuation

Earnings Growth
Earnings for Eli Lilly and are expected to grow by 7.22% in the coming year, from $7.90 to $8.47 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Eli Lilly and is 33.62, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 19.93.
Price to Earnings Ratio vs. Sector
The P/E ratio of Eli Lilly and is 33.62, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 28.72.
Price to Earnings Growth Ratio
Eli Lilly and has a PEG Ratio of 1.95. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Eli Lilly and has a P/B Ratio of 36.94. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Eli Lilly and (NYSE:LLY) Frequently Asked Questions

Is Eli Lilly and a buy right now?

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eli Lilly and in the last twelve months. There are currently 2 hold ratings, 11 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Eli Lilly and stock.
View analyst ratings for Eli Lilly and or view top-rated stocks.

What stocks does MarketBeat like better than Eli Lilly and?

Wall Street analysts have given Eli Lilly and a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Eli Lilly and wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Eli Lilly and's next earnings date?

Eli Lilly and is scheduled to release its next quarterly earnings announcement on Thursday, July 29th 2021.
View our earnings forecast for Eli Lilly and.

How were Eli Lilly and's earnings last quarter?

Eli Lilly and Company (NYSE:LLY) posted its quarterly earnings results on Monday, April, 26th. The company reported $1.87 earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of $2.12 by $0.25. The firm earned $6.81 billion during the quarter, compared to analyst estimates of $7.10 billion. Eli Lilly and had a net margin of 23.91% and a trailing twelve-month return on equity of 132.28%. Eli Lilly and's revenue was up 16.1% compared to the same quarter last year. During the same period in the previous year, the company posted $1.75 earnings per share.
View Eli Lilly and's earnings history.

How has Eli Lilly and's stock price been impacted by Coronavirus?

Eli Lilly and's stock was trading at $140.02 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, LLY shares have increased by 60.8% and is now trading at $225.20.
View which stocks have been most impacted by COVID-19.

How often does Eli Lilly and pay dividends? What is the dividend yield for Eli Lilly and?

Eli Lilly and announced a quarterly dividend on Monday, May 3rd. Stockholders of record on Friday, May 14th will be given a dividend of $0.85 per share on Thursday, June 10th. This represents a $3.40 dividend on an annualized basis and a yield of 1.51%. The ex-dividend date is Thursday, May 13th.
View Eli Lilly and's dividend history.

Is Eli Lilly and a good dividend stock?

Eli Lilly and pays an annual dividend of $3.40 per share and currently has a dividend yield of 1.52%. Eli Lilly and does not yet have a strong track record of dividend growth. The dividend payout ratio of Eli Lilly and is 42.88%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Eli Lilly and will have a dividend payout ratio of 40.14% next year. This indicates that Eli Lilly and will be able to sustain or increase its dividend.
View Eli Lilly and's dividend history.

How will Eli Lilly and's stock buyback program work?

Eli Lilly and announced that its Board of Directors has approved a stock repurchase program on Monday, May 3rd 2021, which allows the company to repurchase $5,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization allows the company to buy up to 2.8% of its stock through open market purchases. Stock repurchase programs are often a sign that the company's management believes its stock is undervalued.

What guidance has Eli Lilly and issued on next quarter's earnings?

Eli Lilly and issued an update on its FY 2021 earnings guidance on Tuesday, May, 4th. The company provided EPS guidance of 7.800-8.000 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $8.230. The company issued revenue guidance of $26.60 billion-$27.60 billion, compared to the consensus revenue estimate of $27.69 billion.

What price target have analysts set for LLY?

14 brokers have issued 1 year price targets for Eli Lilly and's stock. Their forecasts range from $144.00 to $270.00. On average, they expect Eli Lilly and's stock price to reach $207.43 in the next year. This suggests that the stock has a possible downside of 7.9%.
View analysts' price targets for Eli Lilly and or view top-rated stocks among Wall Street analysts.

Who are Eli Lilly and's key executives?

Eli Lilly and's management team includes the following people:

Mr. David A. Ricks, Chairman, CEO & Pres (Age 53, Pay $4.24M) (LinkedIn Profile)
Dr. Daniel M. Skovronsky, Sr. VP, Chief Scientific Officer & Pres of Lilly Research Labs (Age 47, Pay $2.14M) (LinkedIn Profile)
Ms. Anat Hakim J.D., Sr. VP, Gen. Counsel & Sec. (Age 52, Pay $1.72M)
Mr. Alfonso G. Zulueta, Sr. VP & Pres of Lilly International (Age 58, Pay $1.85M)
Mr. Joshua L. Smiley, Exec. Officer (Age 51, Pay $1.04M)
Ms. Anat Ashkenazi, Sr. VP & CFO (Age 48)
Mr. Donald A. Zakrowski, Chief Accounting Officer & VP of Fin.
Mr. Martin Bott MIBS, VP of Fin. & Special Projects (Age 58)
Mr. Diogo Rau, Sr. VP & Chief Information and Digital Officer
Kevin Hern, VP of Investor Relations

What is David A. Ricks' approval rating as Eli Lilly and's CEO?

399 employees have rated Eli Lilly and CEO David A. Ricks on Glassdoor.com. David A. Ricks has an approval rating of 86% among Eli Lilly and's employees.

Who are some of Eli Lilly and's key competitors?

Some companies that are related to Eli Lilly and include Johnson & Johnson (JNJ), Pfizer (PFE), AbbVie (ABBV), Merck & Co., Inc. (MRK), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Horizon Therapeutics Public (HZNP), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Nektar Therapeutics (NKTR), Pacira BioSciences (PCRX), Corcept Therapeutics (CORT), Supernus Pharmaceuticals (SUPN) and Endo International (ENDP).
View all of LLY's competitors.

What other stocks do shareholders of Eli Lilly and own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Eli Lilly and investors own include Johnson & Johnson (JNJ), Pfizer (PFE), NVIDIA (NVDA), Intel (INTC), Cisco Systems (CSCO), Bristol-Myers Squibb (BMY), The Walt Disney (DIS), AT&T (T), Verizon Communications (VZ) and JPMorgan Chase & Co. (JPM).

What is Eli Lilly and's stock symbol?

Eli Lilly and trades on the New York Stock Exchange (NYSE) under the ticker symbol "LLY."

Who are Eli Lilly and's major shareholders?

Eli Lilly and's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Lilly Endowment Inc. (11.50%), BlackRock Inc. (6.16%), The PNC Financial Services Group Inc. (5.44%), Primecap Management Co. CA (3.69%), Price T Rowe Associates Inc. MD (2.73%) and Geode Capital Management LLC (1.40%). Company insiders that own Eli Lilly and stock include Aarti S Shah, Alfonso G Zulueta, Anne E White, David A Ricks, Donald A Zakrowski, Jackson P Tai, Joshua L Smiley, Lilly Endowment Inc, Melissa S Barnes, Myles O'neill and Stephen F Fry.
View institutional ownership trends for Eli Lilly and.

Which institutional investors are selling Eli Lilly and stock?

LLY stock was sold by a variety of institutional investors in the last quarter, including Capital International Investors, Franklin Resources Inc., Primecap Management Co. CA, Janus Henderson Group PLC, Lilly Endowment Inc., Massachusetts Financial Services Co. MA, Robeco Institutional Asset Management B.V., and Bank of Montreal Can. Company insiders that have sold Eli Lilly and company stock in the last year include Alfonso G Zulueta, Donald A Zakrowski, Lilly Endowment Inc, and Melissa S Barnes.
View insider buying and selling activity for Eli Lilly and or view top insider-selling stocks.

Which institutional investors are buying Eli Lilly and stock?

LLY stock was acquired by a variety of institutional investors in the last quarter, including Price T Rowe Associates Inc. MD, Jennison Associates LLC, Ameriprise Financial Inc., Oak Ridge Investments LLC, Rockefeller Capital Management L.P., Bank of New York Mellon Corp, Fisher Asset Management LLC, and Bridge Creek Capital Management LLC. Company insiders that have bought Eli Lilly and stock in the last two years include Anne E White, David A Ricks, Jackson P Tai, and Joshua L Smiley.
View insider buying and selling activity for Eli Lilly and or or view top insider-buying stocks.

How do I buy shares of Eli Lilly and?

Shares of LLY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Eli Lilly and's stock price today?

One share of LLY stock can currently be purchased for approximately $225.20.

How much money does Eli Lilly and make?

Eli Lilly and has a market capitalization of $215.97 billion and generates $24.54 billion in revenue each year. The company earns $6.19 billion in net income (profit) each year or $7.93 on an earnings per share basis.

How many employees does Eli Lilly and have?

Eli Lilly and employs 35,000 workers across the globe.

Does Eli Lilly and have any subsidiaries?

The following companies are subsidiares of Eli Lilly and: 1096401 B.C. Unlimited Liability Company, ARMO BioSciences Inc, ARMO Bioscience, Advanced Cardiovascular Systems, Alnara Pharmaceuticals, Alnara Pharmaceuticals Inc., Andean Technical Operations Center, Applied Molecular Evolution Inc., AurKa Pharma, Avid Radiopharmaceuticals, Avid Radiopharmaceuticals Inc., ChemGen, CoLucid Pharmaceuticals, CoLucid Pharmaceuticals Inc., Dermira, Devices for Vascular Intervention(DVI), Disarm Therapeutics, Dista Ilac Ticaret Ltd. Sti., Dista S.A., Dista-Produtos Quimicos & Farmaceuticos LDA, ELCO Dominicana SRL, ELCO Insurance Company Limited, ELCO Management Inc., ELCO for Trade and Marketing S.A.E., ELGO Insurance Company Limited, Elanco Animal Health Ireland Limited, Elanco Switzerland Holding Sarl, Eli Lilly (Malaysia) Sdn. Bhd., Eli Lilly (Philippines) Incorporated, Eli Lilly (S.A.) (Proprietary) Limited, Eli Lilly (Singapore) Pte. Ltd., Eli Lilly (Suisse) S.A., Eli Lilly Asia Inc., Eli Lilly Asia Pacific SSC Sdn Bhd, Eli Lilly Australia Pty. Limited, Eli Lilly B-H d.o.o., Eli Lilly Benelux S.A., Eli Lilly Bienes y Servicios S de RL de CV, Eli Lilly CR s.r.o., Eli Lilly Canada Inc., Eli Lilly Cork Limited, Eli Lilly Danmark A/S, Eli Lilly Egypt for Trading, Eli Lilly European Clinical Trial Services SA, Eli Lilly Export S.A., Eli Lilly Finance S.A., Eli Lilly Ges.m.b.H., Eli Lilly Group Limited, Eli Lilly Holdings Ltd., Eli Lilly Hrvatska d.o.o., Eli Lilly Interamerica Inc., Eli Lilly Interamerica Inc. y Compania Limitada, Eli Lilly International Corporation, Eli Lilly Ireland Holdings Limited, Eli Lilly Israel Ltd., Eli Lilly Italia S.p.A., Eli Lilly Japan K.K., Eli Lilly Kinsale Limited, Eli Lilly Nederland B.V., Eli Lilly Nigeria Ltd., Eli Lilly Norge A.S., Eli Lilly Pakistan (Pvt.) Ltd., Eli Lilly Polska Sp.z.o.o. (Ltd.), Eli Lilly Regional Operations GmbH, Eli Lilly Romania SRL, Eli Lilly S.A., Eli Lilly Saudi Arabia Limited, Eli Lilly Services Inc, Eli Lilly Services India Private Limited, Eli Lilly Slovakia s.r.o., Eli Lilly Sweden AB, Eli Lilly Vostok S.A. Geneva, Eli Lilly and Company, Eli Lilly and Company (India) Pvt. Ltd., Eli Lilly and Company (Ireland) Limited, Eli Lilly and Company (N.Z.) Limited, Eli Lilly and Company (Taiwan) Inc., Eli Lilly and Company Limited, Eli Lilly de Centro America S.A., Eli Lilly do Brasil Limitada, Eli Lilly farmacevtska druzba d.o.o., Eli Lilly y Compania de Mexico S.A. de C.V., Eli Lilly y Compania de Venezuela S.A., Glycostasis Inc, Greenfield-Produtos Farmaceuticos Lda., Heart Rhythm Technologies Inc, Hybritech, Hypnion, ICOS Corporation, ImClone GmbH, ImClone LLC, ImClone Systems Holdings Inc., ImClone Systems LLC, Imclone Systems, Irisfarma S.A., Ivy Animal Health, Kinsale Financial Services Unlimited Company, Lilly (Shanghai) Management Co. Ltd, Lilly Asia Ventures Fund I L.P., Lilly Asia Ventures Fund II L.P., Lilly Asian Ventures Fund III L.P., Lilly Cayman Holdings, Lilly China Research and Development Co. Ltd., Lilly Deutschland GmbH, Lilly France S.A.S., Lilly Global Nederland Holdings B.V., Lilly Global Services Inc., Lilly Holding GmbH, Lilly Holdings B.V., Lilly Hungaria KFT, Lilly Japan Financing G.K., Lilly Korea Ltd., Lilly Nederland Finance B.V., Lilly Nederland Finance B.V. - GCC, Lilly Nederland Holding B.V., Lilly Pharma Ltd., Lilly Portugal - Produtos Farmaceuticos Lda., Lilly S.A., Lilly Suzhou Pharmaceutical Co. Ltd., Lilly Trading Co. LTD, Lilly USA LLC, Lilly Ventures Fund I LLC, Lilly del Caribe Inc., Lilly ilaç ticaret limited şirketi, Lohmann Animal Health, Loxo Oncology, Lylly Centre for Clinical Pharmacology PTE. LTD., Novartis Animal Health, OY Eli Lilly Finland AB, Origin Medsystems, PT. Eli Lilly Indonesia, Pacific Biotech, Pharmaserve-Lilly S.A.C.I., Physio-Control, SGX Pharmaceuticals, SGX Pharmaceuticals Inc, Spaly Bioquimica S.A., UAB Eli Lilly Lietuva, Valquifarma S.A., and Vital Pharma Productos Farmaceuticos.

When was Eli Lilly and founded?

Eli Lilly and was founded in 1876.

What is Eli Lilly and's official website?

The official website for Eli Lilly and is www.lilly.com.

Where are Eli Lilly and's headquarters?

Eli Lilly and is headquartered at LILLY CORPORATE CENTER, INDIANAPOLIS IN, 46285.

How can I contact Eli Lilly and?

Eli Lilly and's mailing address is LILLY CORPORATE CENTER, INDIANAPOLIS IN, 46285. The company can be reached via phone at 317-276-2000 or via email at [email protected]

This page was last updated on 6/14/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here